Online supplement to: Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial. *The Journal of Rheumatology*. doi:10.3899/jrheum.180681

ONLINE SUPPLEMENTARY DATA


SUPPLEMENTARY TABLE 1. Number (%) of patients with PIC or GO deformity at

baseline and Week 24 by reader (full analysis set for structural damage endpoints)

	IV Placebo	IV Golimumab 2
		mg/kg
Patients randomized, n	239	241
Patients with both baseline and Week 24	215	231
evaluations		
Reader 1		
PIC or GO at baseline	8 (3.7)	5 (2.2)
PIC or GO at Week 24	9 (4.2)	5 (2.2)
Reader 2		
PIC or GO at baseline	23 (10.7)	20 (8.7)
PIC or GO at Week 24	24 (11.2)	21 (9.1)

GO – gross osteolysis, PIC – pencil-in-cup

SUPPLEMENTARY FIGURE 1. Cumulative probability plots of changes in total PsA-modified SHS at week 24 (full analysis set for structural damage endpoints) for patients with (**A**) and without (**B**) NSAID use at baseline and for patients with (**C**) and without (**D**) oral low-dose corticosteroid use at baseline. NSAID - nonsteroidal anti-inflammatory drug, PsA - psoriatic arthritis, SDC - smallest detectable change, SHS - Sharp/van der Heijde Score Online supplement to: Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial. *The Journal of Rheumatology*. doi:10.3899/jrheum.180681



Placebo + Golimumab 2 mg/kg